“Phase 3 trials showed retatrutide produced average weight reduction above 20%.”

Supported with scope

The reviewed evidence supports this exact statement only in the situation described below.

Lilly reported average weight reduction of up to 20.8% in TRIUMPH-2 and up to 22.6% in TRIUMPH-3 at 80 weeks. These are sponsor-reported topline efficacy-estimand figures and group averages, not individual outcomes, and no full peer-reviewed report of either trial was available in the records reviewed here.

What this answer is based on

This answer uses a trial result reported by the study sponsor. A full report checked by other experts may not be available yet.

Limits of this answer

Adults meeting the TRIUMPH-2 (obesity or overweight with type 2 diabetes) and TRIUMPH-3 (severe obesity with established cardiovascular disease) entry criteria at 80 weeks, as disclosed by Lilly in July 2026. These limits show which substance, product, people, use, place, and time the answer covers. A different product or situation can have a different answer.

Topic

What a study measured about people's health, symptoms, or ability to function.